Sentences with phrase «for myeloma cells»
«Preventing the degradation of MBD3 protein will make it difficult for myeloma cells to escape this class of drugs,» said senior author Madhav Dhodapkar, professor of immunobiology and chief of the Section of Hematology.
https://www.sciencedaily.com/
«Synthesizing fatty acids is important for myeloma cells to build vital structures, including cell membranes, that enable them to keep on growing,» Medina said.
Not exact matches
«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Heacell research at Moores Cancer Center at UC San Diego Health.
They are also testing inhibitors of JAK2, a molecule that influences ADAR1 activity, for their ability to eliminate cancer stem cells in multiple myeloma models.
An update search enlarged the pool of study data, but did not change the content of the conclusion of the benefit assessment of stem cell transplantation (SCT) for multiple myeloma conducted in 2012.
«Stem cell transplantation for multiple myeloma: New data did not change conclusion.»
The new findings build on prior research from the Dhodapkar lab demonstrating that patients with Gaucher disease, an inherited lipid storage disorder, have a significant increased risk for developing myeloma; and the discovery of a subset of lipid - reactive immune cells, called type II NKT - TFH, that promote the development of plasma cells.
Myc inhibitors are thought to be promising treatments for multiple myeloma because they shut down a gene required for cell proliferation.
«Therefore, the targeting of Runx2 expression in multiple myeloma cells may represent a new therapeutic strategy for the treatment of aggressive multiple myeloma.»
Whether investigating fat cells, immunotherapy or use of the CRISPR - Cas 9 gene - editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple myeloma, approaches beyond attacking cancer cells are needed in the fight against many cancers.
While some previous studies found that maintenance lenalidomide after autologous hematopoietic stem cell transplant improved overall survival for newly diagnosed multiple myeloma patients, others showed no benefit to this approach.
For this analysis, 605 patients with newly diagnosed multiple myeloma and treated with continuous lenalidomide (brand name Revlimid) following autologous stem cell transplant were compared to 604 patients who were treated with placebo or no maintenance.
«Lenalidomide maintenance following autologous stem cell transplant can now be considered a standard of care for people with multiple myeloma,» says Dr. McCarthy, senior author on the meta - analysis and Principal Investigator of the U.S. study, CALGB (Alliance) 100104.
While the cause of MGUS and multiple myeloma (plasma cell cancer) remains largely unclear, studies have reported an elevated risk of multiple myeloma among farmers and other agricultural workers and pesticides have been thought to be the basis for these associations, according to study background.
«We've known about these cells blocking immune response for a decade, but haven't been able to shut them down for lack of an identified target,» said the paper's senior author, Larry Kwak, M.D., Ph.D., chair of Lymphoma / Myeloma and director of the Center for Cancer Immunology Research at The University of Texas MD Anderson Cancer Center.
«Multiple myeloma patient study shows promise for natural killer cells: Phase I study included combination with high - dose chemotherapy and stem cell transplantation.»
A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths in 2014
Poseida Announces Initial Phase 1 Data for P - BCMA - 101 CAR - T Stem Cell Memory Product in Patients with Relapsed / Refractory Multiple Myeloma
By attaching to the myeloma cells, it marks them for destruction, and by attaching to NK cells, it primes the immune cells to search for and attack the myeloma cells
on Poseida Announces Initial Phase 1 Data for P - BCMA - 101 CAR - T Stem Cell Memory Product in Patients with Relapsed / Refractory Multiple Myeloma
-- Poseida Therapeutics released very early data from a Phase 1 study of its CAR - T cell therapy for multiple myeloma.
We have one of the most comprehensive CAR T cell programs in the world, with 14 CAR T clinical trials ongoing and plans to open numerous additional trials in the coming year, including for patients with multiple myeloma, prostate cancer, liver cancer and breast cancer.
The company is developing CAR T - cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases.
Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
2 top - responding animals are chosen, and immune cells are harvested for fusion with myeloma cells yielding multiple hybridomas.
This enhances the immune response through multiple mechanisms: by attaching to the myeloma cells, it marks them for destruction, and by attaching to the NK cells, it primes the immune cells to search for and attack the myeloma cells.
Another major avenue of immunotherapy for multiple myeloma is adoptive cell transfer.
Heidi Simmons decided to focus on cell therapy for treatment of blood cancers like leukemia, lymphoma and myeloma, where healthy cells are infused into patients to replenish those damaged by cancer.
Plerixafor in combination with granulocyte - colony stimulating factor (G - CSF) has been approved for hematopoietic stem cell mobilization to the peripheral blood in patients with non-Hodgkin's lymphoma and multiple myeloma [54].
For more information from the National Cancer Institute about multiple myeloma and other plasma cell neoplasms, see the following:
No Place Like Home Rebecca Zoltoski was the first patient at the University of Chicago Medicine to undergo a blood and bone marrow stem cell transplant as an outpatient for her multiple myeloma.
CAR T - cell therapy targeting B - cell maturation protein may be a new effective type of immunotherapy treatment for patients with multiple myeloma.
CRP Levels Before Transplant Linked With Survival in Multiple Myeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an autologous stem cell transplantation (ASCT) for multiple myeloma experienced a worse overall survival (OSMyeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an autologous stem cell transplantation (ASCT) for multiple myeloma experienced a worse overall survival (OSmyeloma experienced a worse overall survival (OS) rate.
Stem Cells Make Bone Marrow Cancer Resistant to Treatment Scientists at the Johns Hopkins Kimmel Cancer Center provided evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatmCells Make Bone Marrow Cancer Resistant to Treatment Scientists at the Johns Hopkins Kimmel Cancer Center provided evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatmcells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatmcells and have multiple ways of resisting chemotherapy and other treatments.
Elusive Cancer Stem Cell Identified Johns Hopkins Kimmel Cancer Center scientists have identified the cell likely to be responsible for the development of multiple myeloma, a cancer of the bone marrow that destroys bone tisCell Identified Johns Hopkins Kimmel Cancer Center scientists have identified the cell likely to be responsible for the development of multiple myeloma, a cancer of the bone marrow that destroys bone tiscell likely to be responsible for the development of multiple myeloma, a cancer of the bone marrow that destroys bone tissue.
His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.
Though monoclonal antibodies were a model product in his 18 years CMO experience, process development was also performed for enzymes, hormones, blood factors, immuno - modulants and vaccines with different expression systems such as hybridoma, myeloma, CHO, BHK, insect - cell / baculovirus, adherent animal and human cells.
Additionally, for many blood cell malignancies such as certain types of leukaemia and multiple myeloma, HSC transplantation is an important therapeutic option.
KLF9 - Novel Transcriptional Regulator of Multiple Myeloma Chemotherapy Resistance Multiple myeloma (MM) is a plasma cell disorder that accounts for approximately 10 % of all hematologic malignMyeloma Chemotherapy Resistance Multiple myeloma (MM) is a plasma cell disorder that accounts for approximately 10 % of all hematologic malignmyeloma (MM) is a plasma cell disorder that accounts for approximately 10 % of all hematologic malignancies.
Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation?